Inflammatory Bowel Diseases Highlights From DDW 2022

Raymond Cross, MD


June 22, 2022

Dr Raymond Cross, from the University of Maryland School of Medicine, reports on key findings on inflammatory bowel diseases, presented at Digestive Disease Week 2022.

First, Dr Cross discusses a trial that looks at the effectiveness of a cognitive-behavioral intervention in patients with Crohn's disease. He then presents a phase 4 open-label study evaluating the effect of intravenous vedolizumab dose optimization in refractory patients with moderate to severe ulcerative colitis.

Next, Dr Cross looks at a study determining the environmental factors associated with the risk for Crohn's disease by exploring the "hygiene hypothesis," which suggests that lack of exposure to microbes early in life may negatively affect the immune regulation of microbes as an adult.

Finally, Dr Cross evaluates two studies that discuss biologic therapy, one for use in intolerant patients and the other as part of a triple-therapy combination for patients with high-risk Crohn's disease.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.